The Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 by the Russian government to make investments in leading companies of high-growth sectors of the Russian economy. Its mandate is to co-invest alongside the world’s largest institutional investors — direct investment funds, sovereign wealth funds and leading companies. RDIF therefore acts as a catalyst for direct investment in Russia. RDIF’s reserved capital under management equals $10 billion.
RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant arterial hypertension.
The Russian Direct Investment...
Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.